Maurizio Chiriva-Internati, PhD
Maurizio Chiriva-Internati, PhD, D BSc, is Kiromic’s Chief Executive Officer and Chief Scientific Officer. For the past 20 years, Dr. Chiriva-Internati has investigated tumor antigens as therapeutic and diagnostic tools. His research has led to the identification of novel cancer testis antigens for the development of immunotherapeutic strategies against solid and non-solid tumors. Dr. Chiriva-Internati’s research is focused on developing new therapies for a variety of tumors, including multiple myeloma, acute myeloid leukemia, ovarian, lung, prostate, melanoma, and breast cancer. He is the author of 149 peer-reviewed publications, and is a journal reviewer for The Lancet Infectious Diseases, Cancer Research, The Journal of Immunology, International Reviews of Immunology, and Nature Reviews Clinical Oncology.
Jose A. Figueroa, MD
Jose A. Figueroa, MD serves as Kiromic’s Chief Medical Officer. Dr. Figueroa is a physician-scientist specialized in translational research and Phase I/II clinical trials, and an expert in the diagnosis and treatment of oncologic conditions. He has served as medical director and clinical research director of several cancer centers, as well as Principal Investigator in many multi-center phase I, II and III clinical studies. Dr. Figueroa has participated in the early clinical development of several novel chemotherapeutics (i.e., micellar paclitaxel formulations, exatecan mesylate, temozolomide) and biologicals (i.e., anti-sense oligonucleotides against Protein Kinase C alpha and Hypoxia inducible factor 1, ipilimumab, EGFR antagonists and enzastaurin). Dr. Figueroa is responsible for the design and conduct of early clinical studies in targeted patient populations and the evaluation of safety, immune efficacy and clinical response (phase I/II studies) of Kiromic’s novel immuno-therapeutic strategies.
Gianluca Rotino is Kiromic’s Chief Strategy Officer and Head of Corporate Development. Mr. Rotino is a seasoned business executive with experience in corporate strategy, business development, and capital fund raising. In addition to working for Kiromic, Mr. Rotino holds positions as both CEO and Chairman of the Board for several Italian companies. His previous experience includes senior level managerial positions for companies in Italy in different fields, such as High Tech, International Development and Corporate Consulting. Mr. Rotino worked as a practitioner of international law in Milan, Italy, where he specialized in mergers, acquisitions, intellectual property, and corporate law.
After a highly successful seven-year tenure as Chancellor of the Texas Tech University System, the Honorable Kent R. Hance rejoined his Austin, Texas, law firm. During his tenure at Texas Tech, Chancellor Hance raised more than a $1.2 Billion, increased student enrollment by 45% and added a groundbreaking new medical school in El Paso. Mr. Hance has more than 40 years of experience in the public and private sector as an attorney, businessman, Texas State Senator, U.S. Congressman, Chairman of the Texas Railroad Commission, and Chancellor of the Texas Tech University System. Following six years as a US Congressman, Mr. Hance served on the Texas Railroad Commission (Chairman 1989-1990) which regulates the oil and gas industry in Texas. He has also served on the Governor’s Energy Council, Governor’s Oil Spill Advisory Committee, Texas High Speed Rail Commission, Interstate Oil Compact Commission, and the Texas Mining Council. Mr. Hance presently Chairs Lieutenant Governor Dan Patrick’s Economic Forecast and Advisory Committee. Additional honors include the appointment as Chairman of We Work For Health – Texas, which is a grassroots initiative that unites health consumers, the biopharmaceutical industry, and academia with the goal of improving the healthcare system.
Timothy Cote, MD
Dr. Timothy R. Coté is a leading national regulatory expert in orphan drug development, and served as the Director of the FDA Office of Orphan Products Development (OOPD) from Sept 2007 – May 2011. In this role he implemented the Orphan Drug Act and personally signed decisions on 1400+ orphan drug designation applications. Dr. Coté is founder and CEO at Cote Orphan and has 23 years of federal service at the FDA, NIH, and CDC.
Scott Dahlbeck, MD, PharmD
Scott Dahlbeck, MD, PharmD, is Founder, President and Chief Operating Officer of Kiromic. Dr. Dahlbeck is an expert in prostate cancer research having served as a Radiation Oncologist of several cancer centers. Dr. Dahlbeck has also patented, manufactured, and commercialized intellectual property and has more than a decade of experience in medical and oncology commerce.
Diane D. Nguyen, DO
Dr. Diane Duyen Nguyen is a Founder and Chief of Clinical Development & Medical Affairs. Dr. Nguyen focuses in the clinical development of new immuno-oncology therapeutic treatments and diagnostic tests for both solid tumors and hematologic malignancies. She oversees the clinical trials by designing the programs, monitor them for safety, reporting adverse events, and providing documentation to regulatory agencies. She also works with marketing department to promote the company’s products. Dr. Nguyen is board-certified in Medical Oncology and Hematology. Dr. Nguyen was an Assistant Professor of Medicine in the Division of Hematology/Oncology at the University of Medical Branch in Galveston from 2014 – 2015. She has participated in both clinical trials and translational research in breast and ovarian cancers as well as other solid tumors and hematologic malignancies. She has published papers in the field of Immuno-Oncology for Breast & Ovarian Cancers and other malignancies.
Scott Whitaker, Ph.D., J.D.
Dr. Whitaker began his distinguished career with a dual major and biochemistry and biophysics followed by a PhD in molecular biology, a post-doctoral research fellowship at Harvard Medical School and ultimately a J.D. from the #1 intellectual property law school from George Washington and Suffolk University Schools of Law. He then appointed to the position of Senior Intellectual Property Counsel at Pfizer, charged with opening and establishing the intellectual property legal department for Pfizer’s Drug Discovery and Development Group.
Sharon Tetlow is the managing director of Danforth Advisors in San Francisco which provides COO/CFO level and administrative services for emerging life science and renewable energy companies. Between 2011 and 2013, Tetlow served as CFO for Pathwork Diagnostics, a commercial stage molecular diagnostics company selling an FDA cleared, Medicare reimbursed testing service for difficult to diagnose tumors. Between 1992 and 2009, Sharon has held numerous administrative titles for several companies including Cell Genesys, Apax Partners, diaDexus, Reprogen, Inc., Terrapin and Synergen, Inc.